Search company, investor...

Corvita Corporation

Stage

Acquired | Acquired

About Corvita Corporation

Synthetic grafts for replacing diseased blood vessels. IPO 1994. Acquired by Pfizer in 1996.

Headquarters Location

331 East Evelyn Avenue

Miami, Florida, 94041,

United States

Missing: Corvita Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Corvita Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Corvita Corporation Frequently Asked Questions (FAQ)

  • Where is Corvita Corporation's headquarters?

    Corvita Corporation's headquarters is located at 331 East Evelyn Avenue, Miami.

  • What is Corvita Corporation's latest funding round?

    Corvita Corporation's latest funding round is Acquired.

  • Who are the investors of Corvita Corporation?

    Investors of Corvita Corporation include Pfizer, ONSET Ventures and Trinity Ventures.

  • Who are Corvita Corporation's competitors?

    Competitors of Corvita Corporation include TransMedics, Mercator MedSystems, Endotronix, Light Sciences Oncology, Galil Medical and 11 more.

Compare Corvita Corporation to Competitors

M
Mercator MedSystems

Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

V
Verax Biomedical

Verax Biomedical is the producer of the Platelet PGD Test, a test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the blood banking community while preserving a critical life giving resource.

R
Rafael Medical Technologies

Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.

2
2010 Perfect Vision

20/10 PERFECT VISION OPERATIONS GmbH of Heidelberg, Germany, develops, manufactures and markets technologies for raising refractive surgery well beyond current expectations. The company's expertise lies in diagnostic as well as therapeutic technologies. 20/10 PERFECT VISION's FEMTEC femtosecond laser workstation is set to revolutionize the ophthalmic surgery market, while keeping ease-of-use and patient safety as primary objectives.

L
LifePoint

Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

V
Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.